Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure

Jaehong Kim, Shanshan Wang, Slaven Sikirica, Jason Shafrin
doi: https://doi.org/10.1101/2023.12.05.23299552

Article Information

doi 
https://doi.org/10.1101/2023.12.05.23299552
History 
  • December 6, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Jaehong Kim, PhD1,
  2. Shanshan Wang, MPH1,
  3. Slaven Sikirica, MBA, MSc2 and
  4. Jason Shafrin, PhD1,*
  1. 1FTI Consulting, Center for Healthcare Economics and Policy, Washington, D.C
  2. 2Lexicon Pharmaceuticals, The Woodlands, Texas
  1. ↵*Corresponding Author: Jason Shafrin, PhD, Center for Healthcare Economics and Policy, FTI Consulting United States, California, Los Angeles, Email: jason.shafrin{at}fticonsulting.com, Phone: +1 (858) 366-3983
Back to top
Posted December 06, 2023.
Download PDF
Data/Code
Email
Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure
Jaehong Kim, Shanshan Wang, Slaven Sikirica, Jason Shafrin
medRxiv 2023.12.05.23299552; doi: https://doi.org/10.1101/2023.12.05.23299552
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area